Targeted inhibition of a "signal jammer" protein may improve how tumors respond to immunotherapy. Published today in Nature, ...

TFE3 fusion proteins are the oncogenic drivers of translocation renal cell carcinoma but their mechanism of action remains ...

Favorable initial results from a phase 1/2 trial of solnerstotug in PD-L1–resistant tumors showed a 14% response rate and 62% ...

Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches for precision immunotherapy in oncology and autoimmune diseases, will present updated clinical and ...

Researchers have uncovered a stealth survival strategy that melanoma cells use to evade targeted therapy, offering a ...

The management of breast cancer involves various therapeutic approaches. However, many current anticancer treatments indiscriminately damage both cancerous and healthy cells. In cancer treatment, ...

Early clinical results suggest the firm's antibodies targeting the Vβ T-cell receptor could induce strong and durable responses in cancer patients.

Continues focus on development of bispecific anti-cancer agents with differentiated mechanisms of action SEATTLE, WASHINGTON / ACCESS Newswire / March 18, 2025 / Aptevo Therapeutics (NASDAQ:APVO), a ...

Immunodeficient mouse holding human tumor cells and human immune cells demonstrates tumor metastasis in the lungs. Such tumor metastasis is prevented by short synthetic mRNA injections, as they ...

Discover how blood stem cells release IL-10 to regulate inflammation and protect bone marrow, offering new therapeutic ...

The results showed that the metastases had significantly lower levels of LAMP2A compared to the primary tumors. Similar patterns were observed in metastases from 19 different organs. Cancer cells ...